Physician profile
Sherif M Badawy
NPI 1821355660
$328,696.89
in general payments reported to CMS, 2019-2025
21 companies · $121K in 2025
The $121K reported for 2025 was more than what 99% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $10K · 2021: $20K · 2022: $42K · 2023: $54K · 2024: $70K · 2025: $121K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $182K · Honoraria: $38K · Travel and Lodging: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,909 · Food and Beverage: $4,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $181,523.11 |
| Honoraria | $37,860.00 |
| Travel and Lodging | $14,833.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,909.00 |
| Food and Beverage | $4,134.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $128,909.24 | 2024-2025 | Pyrukynd |
| Vertex Pharmaceuticals Incorporated | $86,625.00 | 2020-2025 | |
| Chiesi USA, INC. | $62,871.78 | 2020-2025 | Ferriprox |
| X4 Pharmaceuticals, INC. | $14,842.82 | 2024-2025 | Xolremdi |
| Bioverativ Therapeutics INC. | $11,208.31 | 2019 | |
| Sobi, INC | $7,706.22 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $4,152.00 | 2022 | |
| Genetix Biotherapeutics INC | $2,800.00 | 2023 | |
| Tersera Therapeutics LLC | $2,196.00 | 2022-2025 | Margenza |
| Global Blood Therapeutics, INC. | $2,177.64 | 2020-2022 | |
| Modernatx, INC. | $2,125.00 | 2021 | |
| Halozyme INC | $609.00 | 2024 | |
| Zoll Medical Corporation | $599.00 | 2023 | |
| Genzyme Corporation | $550.00 | 2021 | |
| Melinta Therapeutics, LLC | $499.00 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $330.13 | 2024-2025 | |
| Celgene Corporation | $162.73 | 2024 | Reblozyl |
| Novo Nordisk INC | $152.13 | 2025 | |
| Emmaus Medical, INC. | $141.54 | 2023 | Endari |
| Novartis Pharmaceuticals Corporation | $39.35 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherif Badawy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.